PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study

Shao‐Liang Chen(Nanjing Medical University), Lijun Liu(Anhui University of Science and Technology), Xiangqi Wu(Model Animal Research Center), Jing Kan(Nanjing Medical University), Wei You(Nanjing Medical University), Fei Ye(Army Medical University), Shenghua Zhou(Central South University), Yonghong Zheng(Liuyang City Maternal and Child Health Hospital), Yan Wang(First Affiliated Hospital of Xiamen University), Zhizhong Liu(Nanjing Medical University), Nailiang Tian(Nanjing Medical University), Xiao-Bo Li(Nanjing Medical University), Xiao-Fei Gao(Nanjing Medical University), Ping Xie(Ganzhou People's Hospital), Hong-Liang Cong(Tianjin Chest Hospital), He-Song Zeng(Tongji Hospital), Lei Zhou(The First People's Hospital of Changzhou), Fan Liu(Hebei Medical University), Rui Li(Harbin Medical University), Xue-Song Qian(Soochow University), Xin Wang(Lianyungang Oriental Hospital), Zhen Ge(Nanjing Medical University), Shang-Yu Wen(Tianjin Central Hospital of Gynecology Obstetrics), Hong-Lei Ji(Jilin University), Jun-Jie Zhang(Nanjing Medical University), Shou-Ming Zhao(Taizhou First People's Hospital), Song Lin(Nanjing Medical University), Jing Chen(Xinjiang Agricultural University)
American Heart Journal
June 27, 2024
Cited by 5


Related Papers